ZymIQ is a pioneering life science company bringing enzyme innovations and therapeutics to the global human and animal health care markets. We develop transformative enzymatic formulations based on the natural defenses of humans and animals to support an active microbial barrier. The enzyme-based antimicrobials either prevent adhesion of microbes to cell surface or kill bacteria.
We also aim to help fight the global threat of increased antibiotic resistance. Through cutting-edge science, we are developing new enzyme-based antibiotics with the possibility to replace or complement future antibiotic treatments.
Our unique enzyme technology platform offer great capabilities and opportunities for the further development and marketing of efficient solutions to improve the lives of humans and animals. The groundbreaking ZymIQ science, delivering exceptional enzyme formulations, has the potential and unique capacity to control the antibiotic resistance threat we are facing today.
When investing in ZymIQ, you not only invest in future innovations and cutting-edge research, but also in improving the health of people and animals, today, tomorrow, and beyond.
ZymIQ investment case
- Research and development in the primary focused sector
- Groundbreaking science with data-driven results
- Innovative and efficient enzyme-based products
- Two technology platforms with a number of synergy effects
- Natural products preserving microflora
- Patent applied technology platforms for several industries
- Previous experience in building businesses
- Strong management competence
ZymIQ has earned a spot on CIO Bulletin’s list of the “5 Best BioTech Companies to Watch in 2023”
We’re delighted to announce that ZymIQ has earned a spot on CIO Bulletin’s list of the “5 Best BioTech Companies to Watch in 2023.” This recognition underscores our commitment and innovative approach in the biotechnology sector.
Read full article here.
Management team and board of directors
Michael Edelborg Christensen
Built Enzymatica from a white piece of paper, took the company through the IPO process and left after 4 years with a market cap of 1 billion SEK
Market and scientific oriented drug and medical device developer. Experience from early drug discovery to market introduction and expansion of medical device products.
Jonas has solid experience from global company building in the Tech world. In a leading position, Jonas has driven development, digitalization and strategy changes to adapt the companies to current and future scenarios. Jonas sat on Enzymatica’s board from 2015 to 2016 and then developed the basis for the company’s expansion.
Göran is the creative link in the board’s work involved in all decisions concerning packaging, form and design. Göran has previous experience in management positions from large and successful companies. Followed his gut feeling 22 years ago and started the advertising agency MMX which specializes in consumer and “retail” needs.
True entrepreneur in the IT sector. Built, expanded, sold and bought back IT companies successfully throughout his career. Strategically always a few steps further which is one of the characteristics of success. Large network in raising capital
Background as an orthopedist in Östergötland County Council, former full-time major in the Karlsborg Armed Forces as a Flight, diver and company doctor. Now Medical responsible SAAB Group nationally and internationally. Researcher at the Royal Institute of Technology, Department of Environmental Physiology
Business lawyer with extensive international legal and business experience. 8 years (2002-2010) as head of Legal, Nordics, Sony Ericsson followed by 2 years (2010-2012) as Head of Portfolio Management at Sony Mobile. 5 years (total) as a lawyer at Sweden’s leading law firms (Vinge, Mannheimer Swartling and Lindahl). Own legal practise since 2013
No planned events